MRC1 and endometrial cancer: We showed that the overall deficiency rate of MMR was 25.2%, within the established range of 17–33% of all ECs (Favier et al., 2022), and approximately 24% of endometrial cancer patients have tumors with MSI-H by PCR-based MSI testing.